Skip to main content

Advertisement

ADVERTISEMENT

Crohn's Disease News

News
08/26/2024
When used after a first-line agent, ustekinumab had significantly better persistence than other biologics.
When used after a first-line agent, ustekinumab had significantly better persistence than other biologics.
When used after a first-line...
08/26/2024
Advances in Inflammatory Bowel Disease Network
News
08/12/2024
Pooled data from induction trials showed improvement in symptoms of Crohn’s disease within a week.
Pooled data from induction trials showed improvement in symptoms of Crohn’s disease within a week.
Pooled data from induction...
08/12/2024
Advances in Inflammatory Bowel Disease Network
News
05/24/2024

Jolynn Tumolo

Jolynn Tumolo
Top-down therapy significantly outperforms step-up treatment for Crohn’s disease with fewer adverse events.
Top-down therapy significantly outperforms step-up treatment for Crohn’s disease with fewer adverse events.
Top-down therapy significantly...
05/24/2024
Advances in Inflammatory Bowel Disease Network

Advertisement

fecal calprotectin test
News
05/09/2024

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
Evidence shows the value of fecal calprotectin to better understand the trajectory of Crohn's disease.
Evidence shows the value of fecal calprotectin to better understand the trajectory of Crohn's disease.
Evidence shows the value of...
05/09/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
04/22/2024
The US Food and Drug Administration approved a subcutaneous formulation of vedolizumab for moderate to severe Crohn's disease.
The US Food and Drug Administration approved a subcutaneous formulation of vedolizumab for moderate to severe Crohn's disease.
The US Food and Drug...
04/22/2024
Advances in Inflammatory Bowel Disease Network
News
03/06/2024

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
The gut microbiome represents a promising avenue to understand shared and distinct pathophysiology among patients with immune-mediated diseases highly concomitant with nonmusculoskeletal inflammatory disorders.
The gut microbiome represents a promising avenue to understand shared and distinct pathophysiology among patients with immune-mediated diseases highly concomitant with nonmusculoskeletal inflammatory disorders.
The gut microbiome represents a...
03/06/2024
Advances in Inflammatory Bowel Disease Network

Advertisement

News
02/12/2024

Priyam Vora, Associate Editor

Priyam Vora, Associate Editor
Investigators examined the prognosis and clinicopathological features of Crohn’s disease-associated colorectal cancer (CRC) compared with sporadic CRC.
Investigators examined the prognosis and clinicopathological features of Crohn’s disease-associated colorectal cancer (CRC) compared with sporadic CRC.
Investigators examined the...
02/12/2024
Advances in Inflammatory Bowel Disease Network
News
02/07/2024

Jolynn Tumolo

Jolynn Tumolo
Early detection and treatment are the keys to reducing risk of progressive disease.
Early detection and treatment are the keys to reducing risk of progressive disease.
Early detection and treatment...
02/07/2024
Gastroenterology
News
01/30/2024

Jolynn Tumolo

Jolynn Tumolo
C-reactive protein and other parameters can show indications of Crohn’s disease up to 8 years before diagnosis.
C-reactive protein and other parameters can show indications of Crohn’s disease up to 8 years before diagnosis.
C-reactive protein and other...
01/30/2024
Gastroenterology

Advertisement

News
01/05/2024

Jolynn Tumolo

Jolynn Tumolo
New guidance focuses on disease management for both asymptomatic and symptomatic patients.
New guidance focuses on disease management for both asymptomatic and symptomatic patients.
New guidance focuses on disease...
01/05/2024
Advances in Inflammatory Bowel Disease Network

Advertisement